These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1866710)

  • 21. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.
    Rote WE; Werns SW; Davis JH; Feigen LP; Kilgore KS; Lucchesi BR
    Cardiovasc Res; 1993 Mar; 27(3):500-7. PubMed ID: 8490951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A porcine model of carotid artery thrombosis for thrombolytic therapy and angioplasty: application of PTFE graft-induced stenosis.
    Lin PH; Chen C; Surowiec SM; Conklin B; Bush RL; Chaikof EL; Lumsden AB; Weiss V
    J Endovasc Ther; 2000 Jun; 7(3):227-35. PubMed ID: 10883961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
    Wong PC; Crain EJ; Knabb RM; Meade RP; Quan ML; Watson CA; Wexler RR; Wright MR; Slee AM
    J Pharmacol Exp Ther; 2000 Oct; 295(1):212-8. PubMed ID: 10991981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A highly reproducible model of arterial thrombosis in rats.
    Guarini S
    J Pharmacol Toxicol Methods; 1996 Apr; 35(2):101-5. PubMed ID: 8729436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.
    Hennan JK; Hong TT; Shergill AK; Driscoll EM; Cardin AD; Lucchesi BR
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1151-6. PubMed ID: 12023550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S; Tschopp T; Baumgartner HR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin inhibition compared with other antithrombotic drugs in rats.
    Schumacher WA; Heran CH; Steinbacher TE; Megill JR; Bird JE; Giancarli MR; Durham SK
    Thromb Res; 1992 Oct; 68(2):157-66. PubMed ID: 1475778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
    Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
    Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis.
    Rote WE; Davis JH; Mousa SA; Reilly TM; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):681-9. PubMed ID: 7516023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs.
    Mousa SA; Mu DX; Lucchesi BR
    Stroke; 1997 Apr; 28(4):830-5; discussion 835-6. PubMed ID: 9099204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries.
    Araki H; Nishi K; Ishihara N; Okajima K
    Thromb Res; 1991 May; 62(3):209-16. PubMed ID: 1891766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study).
    Hong TT; Huang J; Driscoll E; Lucchesi BR
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):526-33. PubMed ID: 16160608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
    Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
    Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
    Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis.
    Ragni M; Cirillo P; Pascucci I; Scognamiglio A; D'Andrea D; Eramo N; Ezekowitz MD; Pawashe AB; Chiariello M; Golino P
    Circulation; 1996 May; 93(10):1913-8. PubMed ID: 8635271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and sonographic patterns of tandem internal carotid artery/middle cerebral artery occlusion in tissue plasminogen activator-treated patients.
    El-Mitwalli A; Saad M; Christou I; Malkoff M; Alexandrov AV
    Stroke; 2002 Jan; 33(1):99-102. PubMed ID: 11779896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.